… Objective Chronic heart failure with reduced ejection fraction (HF-REF) represents a major
… We evaluated the cost-effectiveness of sacubitril/valsartan (formerly LCZ696) compared with …

… showed that Sacubitril/Valsartan did not significantly reduce the overall hospitalization rate
of heart failure and cardiovascular deaths in patients with heart failure and ejection fraction of …

… mortality and the heart failure hospitalization rate. … of heart failure, the efficacy and safety
of sacubitril/valsartan remains uncertain. We aim to study the efficiency of sacubitril/valsartan in …

… failure with reduced ejection fraction due to acquired cardiovascular disease [5,6]. Data …
sacubitril/valsartan in ACHD patients with CHD of moderate/severe complexity and heart failure, …

… Sacubitril/valsartan has been extensively studied in a comprehensive clinical development
programme that focuses on HF ‘Fortifying Heart Failure clinical evidence and patient quality …

… should be used in chronic heart failure and acute myocardial … addition of valsartan to standard
therapy for congestive heart failure, … heart failure, and death, in this cohort with the use of …

… heart failure and death from cardiovascular causes. We examined clinical endpoints and the
safety of sacubitril–valsartan … in blood pressure from the end of valsartan run-in to Weeks 4 …

… in the clinical course of patients with heart failure (HF); the period … The angiotensin
receptor-neprilysin inhibitor sacubitril/valsartan… to sacubitril/valsartan among patients with HFrEF …

… A single measurement of a natriuretic peptide at any time during the progression of chronic
heart failure (HF) provides a clinically useful tool for risk stratification in different clinical …

… valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is a possible
treatment option for chronic heart failure … -effectiveness of sacubitril/valsartan use in South Korea …